source
- Phase 3 trial shows cancer vaccine intismeran autogene cuts recurrence risk by 42% versus KeytrudaAt the European Society for Medical Oncology Congress, a Phase 3 trial of the personalized cancer vaccine intismeran autogene reported a 42% reduction in risk of recurrence or death compared with p…
- FDA releases draft guidance on oversight of individualized gene-editing productsThe U.S. Food and Drug Administration issued draft guidance that outlines a proposed regulatory framework for individualized gene‑editing products, including cases where multiple product variants a…